MacroGenics (MGNX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on MacroGenics (MGNX) is Neutral.

The composite score behind that read is -0.06, weighing +0.07 of bullish evidence against -0.25 bearish.

MacroGenics last closed at $3.74, +5.35% on the session.

Against the IVW growth benchmark the position is +4.55% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

19 graded predictions for MGNX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks MacroGenics in the 4th percentile on return on equity, where 100 is best.

MacroGenics is classified under Health Care / Biotechnology, with a market capitalisation of $226.13M.

StockMap tracks MacroGenics as the 236th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite MacroGenics ranks 162nd of 381 in the group, against a group median of -0.08.